Average Insider

Where insiders trade, we follow

Insider Buy/Sell Details for the Biotechnology Industry — Last 3 Months

Extreme outlier transactions (>3σ) are excluded.Show All Data
Ratio0.1:1
Daily Buy & Sell Volume
Feb 2, 2026
Sale
Shares
1,890
Price
$44.57
Total Value
$84.24K
Shares Held After
3,559,765
% of Holdings
0.1%

Adaptive Biotechnologies Corp (ADPT)

ROBINS HARLAN S — Chief Scientific Officer
Feb 2, 2026
Sale
Shares
34,668
Price
$18.60
Total Value
$644.82K
Shares Held After
1,187,644
% of Holdings
2.8%

Apogee Therapeutics, Inc. (APGE)

Henderson Jane — Chief Financial Officer
Feb 2, 2026
Sale
Shares
100
Price
$66.89
Total Value
$6.69K
Shares Held After
183,371
% of Holdings
0.1%

Apogee Therapeutics, Inc. (APGE)

Henderson Jane — Chief Financial Officer
Feb 2, 2026
Sale
Shares
1,108
Price
$66.15
Total Value
$73.29K
Shares Held After
183,471
% of Holdings
0.6%

Apogee Therapeutics, Inc. (APGE)

Henderson Jane — Chief Financial Officer
Feb 2, 2026
Sale
Shares
792
Price
$65.21
Total Value
$51.65K
Shares Held After
184,579
% of Holdings
0.4%

Arcutis Biotherapeutics, Inc. (ARQT)

Vairavan Latha — SVP Chief Financial Officer
Feb 2, 2026
Sale
Shares
1,320
Price
$25.50
Total Value
$33.66K
Shares Held After
63,607
% of Holdings
2.0%

Arcutis Biotherapeutics, Inc. (ARQT)

Edwards Larry Todd — Reporting Person's title: EVP Chief Commercial Officer
Feb 2, 2026
Sale
Shares
2,052
Price
$25.50
Total Value
$52.32K
Shares Held After
148,865
% of Holdings
1.4%
Feb 2, 2026
Sale
Shares
10,000
Price
$25.05
Total Value
$250.48K
Shares Held After
59,744
% of Holdings
14.3%
Feb 2, 2026
Sale
Shares
19,833
Price
$25.50
Total Value
$505.71K
Shares Held After
721,306
% of Holdings
2.7%

Arcutis Biotherapeutics, Inc. (ARQT)

Burnett Patrick — Reporting Person's Title: Executive Vice President and Chief Medical Officer
Feb 2, 2026
Sale
Shares
3,675
Price
$25.50
Total Value
$93.71K
Shares Held After
90,445
% of Holdings
3.9%
Feb 2, 2026
Sale
Shares
124,998
Price
$18.44
Total Value
$2.30M
Shares Held After
2,459,245
% of Holdings
4.8%
Feb 2, 2026
Sale
Shares
1,890
Price
$44.57
Total Value
$84.24K
Shares Held After
3,559,765
% of Holdings
0.1%
Shares
830
Price
$45.00
Total Value
$37.35K
Shares Held After
12,546
% of Holdings
6.2%

Allogene Therapeutics, Inc. (ALLO)

Parker Geoffrey M. — CHIEF FINANCIAL OFFICER
Feb 2, 2026
Sale
Shares
24,001
Price
$1.76
Total Value
$42.24K
Shares Held After
1,252,795
% of Holdings
1.9%
Feb 2, 2026
Sale
Shares
95,269
Price
$1.80
Total Value
$171.48K
Shares Held After
5,185,862
% of Holdings
1.8%
Feb 2, 2026
Sale
Shares
23
Price
$197.19
Total Value
$4.54K
Shares Held After
43,187
% of Holdings
0.1%
Feb 2, 2026
Sale
Shares
381
Price
$196.36
Total Value
$74.81K
Shares Held After
43,210
% of Holdings
0.9%
Feb 2, 2026
Sale
Shares
23
Price
$195.60
Total Value
$4.50K
Shares Held After
43,591
% of Holdings
0.1%
Feb 2, 2026
Sale
Shares
1
Price
$192.18
Total Value
$192.18
Shares Held After
43,614
% of Holdings
0.0%
Feb 2, 2026
Sale
Shares
39
Price
$191.00
Total Value
$7.45K
Shares Held After
43,615
% of Holdings
0.1%

Allogene Therapeutics, Inc. (ALLO)

Beneski Benjamin Machinas — SVP, Chief Technical Officer
Feb 2, 2026
Sale
Shares
7,549
Price
$1.73
Total Value
$13.06K
Shares Held After
210,172
% of Holdings
3.5%

Maze Therapeutics, Inc. (MAZE)

Bachrodt Amy — SVP, Finance
Feb 2, 2026
Sale
Shares
736
Price
$46.63
Total Value
$34.32K
Shares Held After
12,965
% of Holdings
5.4%

Maze Therapeutics, Inc. (MAZE)

Bachrodt Amy — SVP, Finance
Feb 2, 2026
Sale
Shares
4,064
Price
$46.03
Total Value
$187.07K
Shares Held After
13,701
% of Holdings
22.9%

Maze Therapeutics, Inc. (MAZE)

Bachrodt Amy — SVP, Finance
Feb 2, 2026
Sale
Shares
200
Price
$44.15
Total Value
$8.83K
Shares Held After
17,765
% of Holdings
1.1%
Feb 2, 2026
Purchase
Shares
1,538,462
Price
$1.30
Total Value
$2.00M
Shares Held After
1,538,462
% of Holdings
100.0%

Maze Therapeutics, Inc. (MAZE)

Bernstein Harold — President, R&D & CMO
Feb 2, 2026
Sale
Shares
100
Price
$47.23
Total Value
$4.72K
Shares Held After
0
% of Holdings
100.0%

Maze Therapeutics, Inc. (MAZE)

Bernstein Harold — President, R&D & CMO
Feb 2, 2026
Sale
Shares
5,936
Price
$46.37
Total Value
$275.27K
Shares Held After
100
% of Holdings
98.3%

Maze Therapeutics, Inc. (MAZE)

Bernstein Harold — President, R&D & CMO
Feb 2, 2026
Sale
Shares
8,364
Price
$45.89
Total Value
$383.82K
Shares Held After
6,036
% of Holdings
58.1%

Maze Therapeutics, Inc. (MAZE)

Bernstein Harold — President, R&D & CMO
Feb 2, 2026
Sale
Shares
600
Price
$44.20
Total Value
$26.52K
Shares Held After
14,400
% of Holdings
4.0%
Feb 2, 2026
Sale
Shares
20,070
Price
$5.09
Total Value
$102.17K
Shares Held After
137,722
% of Holdings
12.7%

Absci Corp (ABSI)

Jonasson Zachariah — CFO / CBO
Feb 2, 2026
Sale
Shares
17,496
Price
$2.99
Total Value
$52.31K
Shares Held After
383,538
% of Holdings
4.4%

Absci Corp (ABSI)

McClain Sean — Director
Feb 2, 2026
Sale
Shares
26,761
Price
$2.99
Total Value
$80.02K
Shares Held After
8,334,567
% of Holdings
0.3%
Feb 2, 2026
Sale
Shares
35,700
Price
$1.77
Total Value
$63.19K
Shares Held After
581,166
% of Holdings
5.8%
Feb 2, 2026
Sale
Shares
5,843
Price
$42.08
Total Value
$245.90K
Shares Held After
30,167
% of Holdings
16.2%
Feb 2, 2026
Sale
Shares
102,581
Price
$42.08
Total Value
$4.32M
Shares Held After
292,415
% of Holdings
26.0%
Feb 2, 2026
Sale
Shares
4,167
Price
$1.72
Total Value
$7.17K
Shares Held After
130,322
% of Holdings
3.1%

Allogene Therapeutics, Inc. (ALLO)

Douglas Earl Martin — SVP, General Counsel
Feb 2, 2026
Sale
Shares
22,900
Price
$1.76
Total Value
$40.30K
Shares Held After
564,948
% of Holdings
3.9%
Feb 2, 2026
Sale
Shares
15,500
Price
$14.69
Total Value
$227.62K
Shares Held After
3,363,898
% of Holdings
0.5%

Amylyx Pharmaceuticals, Inc. (AMLX)

Mazzariello Gina — Chief Legal Officer
Feb 2, 2026
Sale
Shares
3,448
Price
$14.65
Total Value
$50.52K
Shares Held After
144,693
% of Holdings
2.3%
Feb 2, 2026
Sale
Shares
15,500
Price
$14.68
Total Value
$227.59K
Shares Held After
3,363,965
% of Holdings
0.5%

Amylyx Pharmaceuticals, Inc. (AMLX)

FRATES JAMES M — Chief Financial Officer
Feb 2, 2026
Sale
Shares
3,557
Price
$14.65
Total Value
$52.10K
Shares Held After
173,547
% of Holdings
2.0%
Feb 2, 2026
Purchase
Shares
100
Price
$58.00
Total Value
$5.80K
Shares Held After
450,944
% of Holdings
0.0%

IONIS PHARMACEUTICALS INC (IONS)

BENNETT C FRANK — EVP, Chief Scientific Officer
Feb 2, 2026
Sale
Shares
16,463
Price
$83.03
Total Value
$1.37M
Shares Held After
80,293
% of Holdings
17.0%

IONIS PHARMACEUTICALS INC (IONS)

BENNETT C FRANK — EVP, Chief Scientific Officer
Feb 2, 2026
Sale
Shares
48,626
Price
$83.03
Total Value
$4.04M
Shares Held After
80,293
% of Holdings
37.7%

IONIS PHARMACEUTICALS INC (IONS)

BENNETT C FRANK — EVP, Chief Scientific Officer
Feb 2, 2026
Sale
Shares
20,000
Price
$82.60
Total Value
$1.65M
Shares Held After
80,293
% of Holdings
19.9%
Feb 2, 2026
Sale
Shares
15,000
Price
$10.72
Total Value
$160.86K
Shares Held After
454,864
% of Holdings
3.2%
Feb 2, 2026
Sale
Shares
83,689
Price
$1.39
Total Value
$116.33K
Shares Held After
3,297,794
% of Holdings
2.5%
Feb 2, 2026
Sale
Shares
114,891
Price
$1.39
Total Value
$159.70K
Shares Held After
3,206,233
% of Holdings
3.5%
Feb 2, 2026
Sale
Shares
96,065
Price
$1.39
Total Value
$133.53K
Shares Held After
3,321,124
% of Holdings
2.8%
Feb 2, 2026
Sale
Shares
46,660
Price
$1.39
Total Value
$64.86K
Shares Held After
3,417,189
% of Holdings
1.3%
Version: v26.3.33